卡托普利、缬沙坦对兔动脉粥样硬化斑块的干预作用  

The effect of captopril and valsartan on preventing the formation of atherosclerotic plaque

作　　者：鹿育萨[1] 雷新宇[1] 邸捷[1] 黄淑田[1] 李建民[2] 

机构地区：[1]山西医科大学第二医院心血管内科,太原030001 [2]山西省肿瘤医院病理科

出　　处：《中华内科杂志》2005年第6期425-427,共3页Chinese Journal of Internal Medicine

基　　金：山西省自然科学基金资助项目(20041114)

摘　　要：目的观察高胆固醇饮食造成兔大动脉粥样斑块形成过程中卡托普利和缬沙坦对大动脉粥样斑块形成的干预作用。方法30只健康雄性新西兰兔随机分为高脂饮食组(A组),高脂饮食加卡托普利组(B组),高脂饮食加缬沙坦组(C组)和对照组(D组)喂养10周后,行超声检测腹主动脉内膜中膜的厚度。并行病理观察血管内膜以及血管内皮细胞情况。结果A组腹主动脉壁粥样斑块形成,血管内膜增厚;B组和C组血管壁有少量粥样斑块形成,血管内膜增厚均较A组明显减轻(P<0.01)。结论卡托普利和缬沙坦具有抗高胆固醇血症致动脉壁粥样斑块形成的确切效果。Objective To observe the effect of captopril and valsartan on preventing the formation of atherosclerosis plaque in rabbit atherosclerotic models. Methods The atherosclerotic models of rabbits fed with high-cholesterol diet were used. There were four groups: high cholesterol group, high cholesterol+captopril group, high cholesterol+valsartan group, normal food group. The intima-media thickness in abdominal aortic were measured by ultrasound. The pathogenic features of the arterial walls were showed by HE stain and observed by light microscope.Results There were less atherosclerotic plaque in high cholesterol+captopril group and high cholesterol+valsartan group than in cholesterol group. The intima-media thickness in high cholesterol+captopril group and in high cholesterol+valsartan group were much more decreased than in high cholesterol group(0.05±0.005,0.05±0.007 vs 0.07±0.100, P<0.01). The connection of the endothelial cells were less damaged in high cholesterol+captopril group and high cholesterol+valsartan group than in high cholesterol group. Conclusions Ti is true that angiotensin converting enzyme inhibitors(ACEI) and angiotensinⅡ receptor blockers(ARB) have the effect of preventing or decreasing the formation of atherosclerotic plaque in arterial wall. The findings suggest that ACEI and/or ARB should be first chosen for those with hypertension and with atherosclerotic risk factors or atherosclerotic diseases.

关 键 词：卡托普利 缬沙坦 兔 动脉粥样硬化斑块 高脂饮食 血管紧张素 受体 

分 类 号：R543.3[医药卫生—心血管疾病]